GE Healthcare has introduced Amersham ECL Prime, a highly sensitive chemiluminescent western blotting reagent for the stable detection of small protein quantities.
Amersham ECL Prime is characterised by stable signal emission up to three hours after addition of the reagent, allowing for the possibility of repeated exposures and making it easier to process several blots in the same experimental run.
High signal intensity means that proteins may be detected using more dilute primary and secondary antibodies, which reduces background noise and reagent consumption.
Amersham ECL Prime is optimised for imaging with Imagequant LAS 4000 (CCD-based imaging) and is compatible with Amersham Hyperfilm.
The reagent is also compatible with Rainbow Molecular Weight Markers and Amersham ECL Dualvue western blotting markers.
It is optimised for use with Amersham Hybond-P (PVDF) membranes and compatible with Amersham Hybond-ECL (nitrocellulose) membranes.
GE Healthcare's enhanced chemiluminescence (ECL) western blotting system portfolio provides tools for applications ranging from routine protein detection to multiplex analysis using fluorescence-based Amersham ECL Plex.
The ECL-based detection method negates the need for handling hazardous radioisotopes, and enables faster, more sensitive and more flexible protein analysis.
